Greenwich LifeSciences’ (GLSI) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Greenwich LifeSciences (NASDAQ:GLSI) in a research note released on Tuesday morning,Benzinga reports. HC Wainwright currently has a $38.00 target price on the stock.

Greenwich LifeSciences Trading Up 2.8 %

NASDAQ:GLSI opened at $12.30 on Tuesday. The company’s 50-day moving average price is $12.65 and its 200-day moving average price is $13.53. The company has a market cap of $161.75 million, a P/E ratio of -15.37 and a beta of 1.69. Greenwich LifeSciences has a twelve month low of $8.70 and a twelve month high of $21.44.

Insiders Place Their Bets

In other news, CEO Snehal Patel bought 3,200 shares of Greenwich LifeSciences stock in a transaction on Monday, December 30th. The shares were bought at an average cost of $11.12 per share, with a total value of $35,584.00. Following the completion of the purchase, the chief executive officer now directly owns 5,539,302 shares of the company’s stock, valued at approximately $61,597,038.24. This trade represents a 0.06 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders have bought 10,500 shares of company stock valued at $128,459 over the last ninety days. Company insiders own 51.67% of the company’s stock.

Hedge Funds Weigh In On Greenwich LifeSciences

A number of institutional investors have recently bought and sold shares of GLSI. State Street Corp raised its stake in shares of Greenwich LifeSciences by 4.4% in the 3rd quarter. State Street Corp now owns 71,408 shares of the company’s stock valued at $1,026,000 after acquiring an additional 3,005 shares during the period. Geode Capital Management LLC raised its stake in shares of Greenwich LifeSciences by 4.6% in the 3rd quarter. Geode Capital Management LLC now owns 133,550 shares of the company’s stock valued at $1,919,000 after acquiring an additional 5,861 shares during the period. Barclays PLC raised its stake in shares of Greenwich LifeSciences by 323.3% in the 3rd quarter. Barclays PLC now owns 8,560 shares of the company’s stock valued at $123,000 after acquiring an additional 6,538 shares during the period. Garden State Investment Advisory Services LLC purchased a new stake in shares of Greenwich LifeSciences in the 3rd quarter valued at approximately $253,000. Finally, Wells Fargo & Company MN raised its stake in shares of Greenwich LifeSciences by 54.8% in the 4th quarter. Wells Fargo & Company MN now owns 2,847 shares of the company’s stock valued at $32,000 after acquiring an additional 1,008 shares during the period. 4.16% of the stock is owned by hedge funds and other institutional investors.

About Greenwich LifeSciences

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.